apparently enrolments have been slower than expected:
" Phase 1b psoriasis patient study is expected to be fully enrolled by the end of 1Q CY2019 with top line data expected in Q2 CY2019."
Since this trial is in collaboration ......I'd blame BIOSKIN for it.
Net tangible assets per security reads fine
Ann: Half Yearly Report and Accounts, page-5
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
32.3¢ |
Change
0.008(2.38%) |
Mkt cap ! $707.4M | |||
| Open | High | Low | Value | Volume |
| 31.5¢ | 32.5¢ | 31.0¢ | $512.9K | 1.611M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 131231 | 32.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 32.5¢ | 560050 | 10 |
View Market Depth
| Last trade - 11.59am 22/11/2024 (20 minute delay) ? |
| BOT (ASX) Chart |
